Telix Pharmaceuticals (ASX:TLX) reported strong commercial and operational performance for the quarter ended Dec. 31, 2025, achieving its upgraded full-year FY25 revenue guidance with unaudited group revenue of approximately US$804 million.
Fourth-quarter revenue reached about US$208 million, representing 46% year-on-year growth and reflecting accelerating momentum across the business.
Precision Medicine revenue rose to approximately US$161 million, up 4% quarter-on-quarter, driven primarily by the successful US launch of Gozellix following reimbursement approval from the Centers for Medicare and Medicaid Services effective October 2025.
The company said the two-product PSMA strategy, encompassing Illuccix and Gozellix, supported gains in market share and pricing, with revenue growth exceeding dose volume growth.
Telix also reported progress across its therapeutic pipeline, including the first international patients dosed in Part 2 of the Phase 3 ProstACT Global study of TLX591-Tx in advanced prostate cancer and the first US patients treated in the SOLACE Phase 1 study of TLX090-Tx for bone metastasis pain.
During the quarter, Telix announced a strategic collaboration with Varian, a Siemens Healthineers company, to explore combining its radiopharmaceuticals with external beam radiation therapy.
Managing Director and CEO Dr Christian Behrenbruch said early uptake of Gozellix and continued integration of Telix products and manufacturing technologies positioned the company for sustained growth in 2026, supported by expanding global clinical programs, regulatory progress in key markets, and ongoing investment in manufacturing and supply-chain infrastructure.